Xingquan Ma, Ph.D.

Senior Vice President, Chemistry Department

Xingquan Ma, used to be an associate researcher of the Scripps Institute (TSRI) and a visiting scholar of the National lnstitutes of Health (NIH). He received doctor's degree from Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences. In 2018, he joined Medicilon as Vice President of the Chemical Department.

Dr. Xingquan Ma has studied and worked at the top academic institutions in China and the US. He has in-depth research in the field of glycan chemistry and biology. He has extensive knowledge and experience in the isolation, extraction and chemical synthesis of saponins, the active ingredients of Chinese herbal medicine. He has more research on the synthesis and biological activity of polysaccharide macromolecular adducts in the frontier field. He is interested in the crystaline structure of cellular membrane proteins,especially in the crystallization of glycolipids on penetrating membrane proteins and the high-resolution analysis of their structures. He has also worked on the synthesis and bioactivity of polyphenols, including teicoplanin, and more complex oligomers.Xingquan Ma, has 12 years of experience in corporate drug discovery and development,and has collaborated with several European and American companies in novel drug research. He has published more than 20 academic papers in domestic and international core journals, including JACS, ANGEW, LANGMUIR,OBC,JMCL. etc.

Yieyie Yang, Ph.D., J.D.

Of Counsel, Finnegan, Henderson, Farabow, Garrett &Dunner, LLP

Yieyie Yang, Ph.D in Molecular Biology, J.D., is Of Counsel at Finnegan, Henderson,Farabow, Garrett & Dunner, LLP, a top tier global law firm specialized in Intellectua Property legal matters. Dr. Yang has extensive experience representing pharmaceutical and biotech companies in a wide variety of IP matters, including patent prosecution,client counseling, due diligence, licensing, patent post-grant proceedings, patent litigation,and appeal. Dr. Yang has assisted large international pharmaceutical companies such as Eli Lilly, AstraZeneca, AbbVie, GSK, Merck, Novartis, and rising startup biotech companies during fund-raising and early to late R&D stages on IP matters. Specifically,Dr. Yang represented patent owners or petitioners in over 35 IPRS/PGRs involving biotech patents. Dr. Yang was awarded among "Ones to Watch" in 2023 by Best Lawyers for her outstanding professional excellence in private practice in patent law in theUnited States.

Mark Feldstein, Ph.D., J.D.

Partner, Finnegan, Henderson, Farabow, Garrett &Dunner, LLP

Mark Feldstein, Ph.D., J.D. a Partner at Finnegan, Henderson, Farabow, Garrett &Dunner, LLP, a top tier global law firm specialized in Intellectual Property legal matters.Dr. Feldstein has more than 20 years of experience in U.S. district court and appellate litigation concerning the enforcement of U.S. patent rights and trade secret issues aswell as extensive experience in post-grant trial proceedings (IPRs and PGRs) at the U.S. Patent and Trademark Office. His practice encompasses a range of technologies, including pharmaceuticals, biotechnology, and small molecule chemistry. This includes having litigated patent validity and infringement on behalf of large and small biopharmaceutical companies, such as Eli Lilly, AstraZeneca, Incyte, Cephalon, and Cumberland Pharmaceuticals. In addition, Dr. Feldstein is an adjunct professor of law at Georgetown University Law Center, teaching courses in patent prosecution strategy.He speaks regularly to national and international audiences of both attorneys and scientists on issues of patent strategy, prosecution, and litigation. Dr. Feldstein is also an associate editor for texts published by the American Bar Association Section of Intellectual Property Law on Abbreviated New Drug Application (ANDA) litigation law and strategy, and by AIPLA/Bloomberg BNA on evidence in patent litigations.

Karsten Holm

Director of Business Development at Medicilon